Apppublic
VIDraft/AI

sourceHugging Faceapache-2.0updated 1d agoView on Hugging Face
22likes
bio.html75 linesDownload Raw Back to press
1<!doctype html>
2<html lang="ko">
3<head>
4<meta charset="utf-8"><meta name="viewport" content="width=device-width, initial-scale=1">
5<title>신약 · 바이오 — 비드래프트 언론보도 · VIDRAFT</title>
6<meta name="description" content="AI 신약 탐색과 바이오 분야 협력에 관한 보도입니다.">
7<meta name="keywords" content="AI 신약개발, 신약 후보물질, 항암 신약, 펩타이드 예측, ADMET, 오픈 신약탐색">
8<link rel="canonical" href="https://vidraft.net/press/bio.html">
9<link rel="alternate" hreflang="ko" href="https://vidraft.net/press/bio.html">
10<link rel="alternate" hreflang="en" href="https://vidraft.net/press/en/bio.html">
11<link rel="alternate" hreflang="x-default" href="https://vidraft.net/press/en/bio.html">
12<meta property="og:type" content="website"><meta property="og:title" content="신약 · 바이오 — 비드래프트 언론보도 · VIDRAFT">
13<meta property="og:description" content="AI 신약 탐색과 바이오 분야 협력에 관한 보도입니다."><meta property="og:url" content="https://vidraft.net/press/bio.html">
14<meta property="og:site_name" content="VIDRAFT"><meta property="og:locale" content="ko_KR">
15<meta name="twitter:card" content="summary_large_image">
16<meta name="robots" content="index, follow, max-image-preview:large">
17<link rel="preconnect" href="https://fonts.googleapis.com"><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
18<link href="https://fonts.googleapis.com/css2?family=Space+Grotesk:wght@500;600;700&family=JetBrains+Mono:wght@400;500;600&display=swap" rel="stylesheet">
19<link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/orioncactus/pretendard@v1.3.9/dist/web/static/pretendard.min.css">
20<style>
21:root{--bg:#FBFCFE;--surface:#fff;--ink:#131A26;--ink2:#3A4657;--muted:#697689;--line:#E7ECF3;--acc:#4338CA;--acc2:#0E9C7E;
22--sans:'Pretendard','Inter',system-ui,'Apple SD Gothic Neo',sans-serif;--disp:'Space Grotesk','Pretendard',system-ui,sans-serif;--mono:'JetBrains Mono',ui-monospace,Consolas,monospace}
23*{box-sizing:border-box}html,body{overflow-x:clip}
24body{margin:0;background:var(--bg);color:var(--ink);font-family:var(--sans);line-height:1.72;font-size:17px;letter-spacing:-.006em;-webkit-font-smoothing:antialiased}
25a{color:var(--acc);text-decoration:none}a:hover{text-decoration:underline}
26.top{border-bottom:1px solid var(--line);background:rgba(255,255,255,.86);backdrop-filter:blur(10px);position:sticky;top:0;z-index:10}
27.top .in{max-width:1080px;margin:0 auto;padding:12px 22px;display:flex;align-items:center;gap:14px}
28.top .brand{font-family:var(--disp);font-weight:700;font-size:19px;letter-spacing:-.03em;color:var(--ink)}
29.top .brand span{color:var(--acc)}
30.top nav{margin-left:auto;display:flex;align-items:center;gap:10px;font-size:14px}
31.top nav a.txt{color:var(--ink2);padding:6px 4px}
32.top nav a.txt:hover{color:var(--ink)}
33.lang{font-family:var(--mono);font-size:12px;font-weight:600;color:var(--ink2);border:1px solid var(--line);border-radius:8px;padding:6px 10px}
34.lang:hover{border-color:var(--acc);color:var(--acc);text-decoration:none}
35.homebtn{font-weight:600;font-size:13px;color:#fff;background:var(--ink);border-radius:9px;padding:8px 15px;display:inline-flex;align-items:center;gap:6px}
36.homebtn:hover{background:#000;text-decoration:none}
37main{max-width:720px;margin:0 auto;padding:0 22px 90px}
38.crumb{font-size:13px;color:var(--muted);margin:26px 0 10px;font-family:var(--mono)}.crumb a{color:var(--muted)}
39.eyebrow{font-family:var(--mono);font-size:12px;font-weight:600;letter-spacing:.08em;text-transform:uppercase;color:var(--acc)}
40h1{font-family:var(--disp);font-weight:700;font-size:clamp(1.9rem,3.4vw,2.6rem);letter-spacing:-.03em;line-height:1.16;margin:.5rem 0 .4rem}
41.dek{font-size:1.12rem;color:var(--ink2);line-height:1.6;margin:0 0 18px}
42.meta{display:flex;flex-wrap:wrap;gap:16px;font-size:13px;color:var(--muted);font-family:var(--mono);border-top:1px solid var(--line);border-bottom:1px solid var(--line);padding:12px 0;margin-bottom:30px}
43.tldr{background:linear-gradient(180deg,color-mix(in srgb,var(--acc) 7%,#fff),#fff);border:1px solid color-mix(in srgb,var(--acc) 22%,var(--line));border-radius:14px;padding:18px 20px;margin:0 0 34px}
44.tldr .lab{font-family:var(--mono);font-size:11px;font-weight:600;letter-spacing:.1em;text-transform:uppercase;color:var(--acc);margin-bottom:6px}
45.tldr p{margin:0;font-size:1.04rem;color:var(--ink)}
46h2{font-family:var(--disp);font-weight:600;font-size:1.42rem;letter-spacing:-.02em;line-height:1.25;margin:42px 0 4px}
47.ans{border-left:3px solid var(--acc2);background:#F4FBF9;border-radius:0 10px 10px 0;padding:13px 16px;margin:12px 0 14px;color:var(--ink);font-size:1.02rem}
48p{margin:0 0 16px}
49.faq{margin-top:52px;border-top:1px solid var(--line);padding-top:26px}.faq h2{margin-top:0}
50.faq dt{font-family:var(--disp);font-weight:600;font-size:1.06rem;margin-top:20px}.faq dd{margin:6px 0 0;color:var(--ink2)}
51.src{margin-top:46px;border-top:1px solid var(--line);padding-top:22px;font-size:14px}
52.src h3{font-family:var(--mono);font-size:12px;letter-spacing:.06em;text-transform:uppercase;color:var(--muted);font-weight:600;margin:0 0 10px}
53.src ul{margin:0;padding-left:18px;color:var(--ink2)}.src li{margin:4px 0}
54.rel{margin-top:40px;display:grid;gap:12px}
55.rel a{display:block;border:1px solid var(--line);border-radius:12px;padding:14px 16px;background:var(--surface);color:var(--ink)}
56.rel a:hover{border-color:color-mix(in srgb,var(--acc) 40%,var(--line));text-decoration:none}
57.rel .k{font-family:var(--mono);font-size:11px;color:var(--acc);text-transform:uppercase;letter-spacing:.05em}
58.rel .t{font-family:var(--disp);font-weight:600;margin-top:3px}
59.backhome{margin-top:44px;text-align:center}
60.disc{margin-top:30px;font-size:12.5px;color:var(--muted);line-height:1.7}
61footer{border-top:1px solid var(--line);margin-top:60px}
62footer .in{max-width:1080px;margin:0 auto;padding:26px 22px;display:flex;flex-wrap:wrap;gap:12px 24px;align-items:center;font-size:13px;color:var(--muted)}
63footer .brand{font-family:var(--disp);font-weight:700;color:var(--ink)}footer .brand span{color:var(--acc)}
64@media(prefers-color-scheme:dark){:root{--bg:#0C111A;--surface:#121A26;--ink:#E9EEF6;--ink2:#B9C3D2;--muted:#8492A6;--line:#212C3C;--acc:#8B93FF;--acc2:#2FD3B2}
65.top,.tldr{background:rgba(18,26,38,.86)}.ans{background:#0F1B22}.rel a{background:var(--surface)}.homebtn{background:var(--acc);color:#0C111A}.homebtn:hover{background:#a7adff}}
66
67.plist{list-style:none;padding:0;margin:18px 0 0}
68.plist li{padding:13px 0;border-bottom:1px solid var(--line);display:flex;gap:14px;align-items:baseline;flex-wrap:wrap}
69.pdate{font-family:var(--mono);font-size:.82rem;color:var(--muted);min-width:92px}
70.psrc{font-size:.82rem;font-weight:700;color:var(--acc2);min-width:96px}
71.ptit{flex:1;min-width:240px}
72.tnav{display:flex;flex-wrap:wrap;gap:8px;margin:16px 0 0}
73.tnav a{font-size:.86rem;font-weight:700;padding:7px 13px;border:1px solid var(--line);border-radius:999px;background:var(--surface)}
74</style>
75</head><body><header class="top"><div class="in"><a class="brand" href="/">VIDRAFT<span>.</span></a><nav><a class="txt" href="/insights/index.html">인사이트</a><a class="lang" href="./en/bio.html" hreflang="en">EN</a><a class="homebtn" href="/">↖ 홈</a></nav></div></header><main><div class="crumb"><a href="/">VIDRAFT</a> / <a href="./index.html">언론보도</a> / 신약 · 바이오</div><div class="eyebrow">언론보도</div><h1>신약 · 바이오</h1><p class="dek">AI 신약 탐색과 바이오 분야 협력에 관한 보도입니다.</p><div class="meta"><span>보도 8건</span><span>2025-06-05 ~ 2026-08-23</span><span>by VIDRAFT</span></div><div class="tldr"><div class="lab">한눈에</div><p>공개 신약 탐색 챌린지(Open Discovery Challenge), 항균 펩타이드 예측 검증, 세포 기반 실험 검증 협력 등 신약·바이오 영역의 활동이 보도된 기록입니다.</p></div><div class="tnav"><a href="./gov.html">정부 국책과제 · 공공 협력</a><a href="./bench.html">글로벌 벤치마크 기록</a><a href="./model.html">모델 · 아키텍처</a><a href="./infer.html">추론 가속 · 서빙</a><a href="./device.html">온디바이스 · 경량화</a><a href="./bio.html" style="border-color:var(--acc);color:var(--acc)">신약 · 바이오</a><a href="./biz.html">사업 · 협력</a><a href="./index.html">전체 보도 목록</a></div><section><h2>신약 · 바이오 관련 보도</h2><ul class="plist"><li><span class="pdate">2026-08-23</span><span class="psrc">비젠메디컬</span><span class="ptit"><a href="https://medical.vizensoft.com/insight/read?no=827" target="_blank" rel="noopener nofollow">비젠메디컬 분석 — 말라리아·결핵 AI 신약, 클로드 43.7점 초기 데이터가 던진 질문</a></span></li><li><span class="pdate">2026-08-22</span><span class="psrc">RuntimeWire (영문)</span><span class="ptit"><a href="https://runtimewire.com/article/final-bench-drug-prediction-data-split-auroc" target="_blank" rel="noopener nofollow">영문 IT매체 RuntimeWire 보도 — FINAL-Bench, 데이터 분할 방식만 바꿔 AUROC 0.21 격차 확인 (신약 예측 벤치마크 LEADBOARD)</a></span></li><li><span class="pdate">2026-08-19</span><span class="psrc">AP News (미국)</span><span class="ptit"><a href="https://apnews.com/press-release/getnews/press-release-7c16400a122d6b323da715ae50c82c35" target="_blank" rel="noopener nofollow">美 AP News 보도자료 게재 — OpenAI·Claude·Gemini·DeepSeek 중 누가 더 나은 신약 후보를 찾는가 (Open Discovery Challenge)</a></span></li><li><span class="pdate">2026-08-18</span><span class="psrc">AI타임스</span><span class="ptit"><a href="https://www.aitimes.com/news/articleView.html?idxno=214044" target="_blank" rel="noopener nofollow">비드래프트, AI 신약발견 프로젝트 공개…3일 만에 2000건 이상 후보물질 제출</a></span></li><li><span class="pdate">2026-08-18</span><span class="psrc">전자신문</span><span class="ptit"><a href="https://www.etnews.com/20260818000184" target="_blank" rel="noopener nofollow">말라리아·결핵 실제 신약 후보 경쟁서 클로드 계열 선두</a></span></li><li><span class="pdate">2026-07-08</span><span class="psrc">IT조선</span><span class="ptit"><a href="https://it.chosun.com/news/articleView.html?idxno=2023092165374" target="_blank" rel="noopener nofollow">비드래프트 모델 병합 기술 ‘다윈’, 中 기술매체서 조명</a></span></li><li><span class="pdate">2026-02-26</span><span class="psrc">ANVI (이스라엘)</span><span class="ptit"><a href="https://anvi.co.il/blog/final-bench-agi-self-correction-bottleneck-mm282482" target="_blank" rel="noopener nofollow">이스라엘 AI매체 ANVI, FINAL-Bench 심층분석 — “AI는 자기 오류를 고칠 수 있는가”(AGI 자기교정 병목)</a></span></li><li><span class="pdate">2025-06-05</span><span class="psrc">브런치</span><span class="ptit"><a href="https://news.google.com/rss/articles/CBMiR0FVX3lxTE9yUzBGbi1RcWduZHEwcXJFLW1jcEROcjFfZkszTGlSVHRHcG5VZi1KVWx1TUVhZXBDRXJ3RXJDNjlvUUpLZDc4?oc=5" target="_blank" rel="noopener nofollow">의료 AI의 &#x27;거짓말 탐지기&#x27;가 등장했다!</a></span></li></ul></section><div class="src"><h3>안내</h3><p>각 항목은 해당 언론사가 보도한 기사로 연결됩니다. 기사 본문의 저작권은 각 언론사에 있습니다.</p></div><script type="application/ld+json">{"@context": "https://schema.org", "@type": "CollectionPage", "name": "신약 · 바이오 — 비드래프트 언론보도 · VIDRAFT", "description": "AI 신약 탐색과 바이오 분야 협력에 관한 보도입니다.", "inLanguage": "ko", "url": "https://vidraft.net/press/bio.html", "isPartOf": {"@type": "WebSite", "name": "VIDRAFT", "url": "https://vidraft.net"}, "publisher": {"@type": "Organization", "name": "VIDRAFT", "url": "https://vidraft.net"}, "mainEntity": {"@type": "ItemList", "numberOfItems": 8}}</script></main><footer><div class="in"><span class="brand">VIDRAFT<span>.</span></span><span>Pre-AGI · On-device · Quantum · Physical AI</span><a href="/">vidraft.net</a></div></footer></body></html>